245 related articles for article (PubMed ID: 30518684)
1. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.
Wang Y; Zong X; Mitra S; Mitra AK; Matei D; Nephew KP
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518684
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic targeting of ovarian cancer stem cells.
Wang Y; Cardenas H; Fang F; Condello S; Taverna P; Segar M; Liu Y; Nephew KP; Matei D
Cancer Res; 2014 Sep; 74(17):4922-36. PubMed ID: 25035395
[TBL] [Abstract][Full Text] [Related]
3. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
Meng E; Mitra A; Tripathi K; Finan MA; Scalici J; McClellan S; Madeira da Silva L; Reed E; Shevde LA; Palle K; Rocconi RP
PLoS One; 2014; 9(9):e107142. PubMed ID: 25216266
[TBL] [Abstract][Full Text] [Related]
4. L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling.
Giordano M; Decio A; Battistini C; Baronio M; Bianchi F; Villa A; Bertalot G; Freddi S; Lupia M; Jodice MG; Ubezio P; Colombo N; Giavazzi R; Cavallaro U
J Exp Clin Cancer Res; 2021 Oct; 40(1):319. PubMed ID: 34645505
[TBL] [Abstract][Full Text] [Related]
5. Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer.
Atwani R; Nagare R; Rogers A; Prasad M; Lazar V; Sandusky G; Tong Y; Pin F; Condello S
J Exp Clin Cancer Res; 2024 Jun; 43(1):156. PubMed ID: 38822429
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic effects of luteolin on radio-sensitivity enhancement and interleukin-6/signal transducer and activator of transcription 3 signaling repression of oral cancer stem cells.
Tu DG; Lin WT; Yu CC; Lee SS; Peng CY; Lin T; Yu CH
J Formos Med Assoc; 2016 Dec; 115(12):1032-1038. PubMed ID: 27742160
[TBL] [Abstract][Full Text] [Related]
7. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK
Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728
[TBL] [Abstract][Full Text] [Related]
8. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
[No Abstract] [Full Text] [Related]
9. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.
Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z
Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365
[TBL] [Abstract][Full Text] [Related]
10. STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway.
Xu S; Yue Y; Zhang S; Zhou C; Cheng X; Xie X; Wang X; Lu W
J Exp Clin Cancer Res; 2018 Dec; 37(1):305. PubMed ID: 30518424
[TBL] [Abstract][Full Text] [Related]
11. Esculentoside A suppresses breast cancer stem cell growth through stemness attenuation and apoptosis induction by blocking IL-6/STAT3 signaling pathway.
Liu C; Dong L; Sun Z; Wang L; Wang Q; Li H; Zhang J; Wang X
Phytother Res; 2018 Nov; 32(11):2299-2311. PubMed ID: 30080291
[TBL] [Abstract][Full Text] [Related]
12. Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer.
Nieddu V; Melocchi V; Battistini C; Franciosa G; Lupia M; Stellato C; Bertalot G; Olsen JV; Colombo N; Bianchi F; Cavallaro U
Cell Death Dis; 2023 Mar; 14(3):220. PubMed ID: 36977707
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
14. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.
Kim D; Choi BH; Ryoo IG; Kwak MK
Cell Death Dis; 2018 Aug; 9(9):896. PubMed ID: 30166520
[TBL] [Abstract][Full Text] [Related]
15. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
16. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8/STAT3 signaling.
Ning Y; Cui Y; Li X; Cao X; Chen A; Xu C; Cao J; Luo X
Biomed Pharmacother; 2018 Jul; 103():262-271. PubMed ID: 29656182
[TBL] [Abstract][Full Text] [Related]
17. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
18. A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer.
Muralikrishnan V; Fang F; Given TC; Podicheti R; Chtcherbinine M; Metcalfe TX; Sriramkumar S; O'Hagan HM; Hurley TD; Nephew KP
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884498
[TBL] [Abstract][Full Text] [Related]
19. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
20. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.
Visus C; Wang Y; Lozano-Leon A; Ferris RL; Silver S; Szczepanski MJ; Brand RE; Ferrone CR; Whiteside TL; Ferrone S; DeLeo AB; Wang X
Clin Cancer Res; 2011 Oct; 17(19):6174-84. PubMed ID: 21856769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
